Lateral Pharma Pty Ltd Is A Privately Owned Melbourne Au Based Biotechnology Company That Commenced Operations In May 2015 To Repurpose Lat8881A Phase 2 Ready Orally Available Compound With Extensive Toxicology And Human Safety Datainto New High Potential Pain And Respiratory Indicationslateral Aims To Demonstrate Efficacy In A Human Clinical Phase 2 Proof Of Concept Study Using Lat8881 To Treat Neuropathic Pain Within The Next 12 Months Lateral Pharma Has Discovered A New Class Of Naturally Derived Peptide Motifs And Their Novel Target Family Of Proteins That Restore Normal Tissue Function In Mammals Under Conditions Of Damage And Cellular Stresssmall Synthetic Peptides Derived From Growth Hormone And At Least Three Other Proteins Are Active In Animal Models Of Neuropathic Painosteoarthritisobesitycopdsevere Influenza A And Recently In Initial Data In Sars Cov 2 Lateral Has Filed Multiple Patents Protecting Its Intellectual Property Lateral Is Focussed On Developing Its Drugs For The Treatment Of Neuropathic Pain But Subject To Additional Funding Will Also Explore Development In Respiratory Diseases Such As Influenzasars Cov 2Copdsteroid Resistant Asthmaand Post Covid Syndromelong Covid
No conferences found for this company.
| Company Name | Lateral Pharma Pty Ltd |
| Country |
Australia
|
| Address | N/A |
| Telephone | N/A |
| N/A |
